Previous 10 | Next 10 |
Oppenheimer has begun Trevi Therapeutics (NASDAQ:TRVI) with an overweight rating citing the potential of its candidate Haduvio (nalbuphine ER) specifically for chronic cough associated with idiopathic pulmonary fibrosis. Haduvio is in phase 2 for that indication. It is also in phase 2 for chr...
Gainers: Wendy's Company (The) (WEN) +13%. WalkMe (WKME) +8%. Trevi Therapeutics (TRVI) +7%. Braze (BRZE) +6%. Photronics (PLAB) +6%. Losers: Verrica Pharmaceuticals (VRCA) -32%. InterDigital (IDCC) -8%. Chinook Therapeutics (KDNY) -7%. Grindrod Shipping Holdings (...
Trevi Therapeutics, Inc. (TRVI) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants ...
Trevi Therapeutics press release (NASDAQ:TRVI): Q1 GAAP EPS of -$0.24 beats by $0.04. As of March 31, 2022, the Company had total cash and cash equivalents of $29.1 million. For further details see: Trevi Therapeutics GAAP EPS of -$0.24 beats by $0.04
Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update PR Newswire Accelerated planning for next phase of development of Haduvio for the treatment of chronic cough in IPF based on results from statistically significant interim analysis of...
Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022 PR Newswire Conference Call and Webcast to be Held at 4:30 p.m. EDT NEW HAVEN, Conn. , May 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc....
Trevi Therapeutics to Present at Upcoming May Meetings PR Newswire NEW HAVEN, Conn. , May 3, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™...
Dolphin Entertainment (DLPN) +26% on FY results. Airgain (AIRG) +13% on multimillion-dollar contract by major utility. CBAK Energy Technology (CBAT) +12% on Q4 results. Takung Art (TKAT) +8%. Veru (VERU) +7% breather over as stock gains. Metromile (MILE...
Gainers: Eargo (EAR) +13%. Intel Corporation (INTC) +6%. eHealth (EHTH) +4%. Trevi Therapeutics (TRVI) +3%. Pacific Biosciences of California (PACB) +3%. Losers: Protagonist Therapeutics (PTGX) -34%. Cambium Networks Corporation (CMBM) -12%. Vir Biotechnology (VIR) -...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips EVgo (NASDAQ: EVGO ) stock is in the news Friday following news that the electric vehicle (EV) charging company signed a deal with Chase. Source: Sundry Photography / Shutterstock.com The banking division of ...
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events PR Newswire Two abstracts accepted for oral presentation at the 13 th London International Cough Symposium NEW HAVEN, Conn. , July 2, 2024 /PRNewswire/ -- Trevi Therapeutic...
Trevi Therapeutics to Participate in Upcoming Conferences PR Newswire NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of...